

# Manuel LÃ³pez Meseguer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8450160/publications.pdf>

Version: 2024-02-01

68  
papers

1,753  
citations

411340

20  
h-index

340414

39  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2665  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2022, 12, 5289.	1.6	6
2	Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. <i>Journal of Internal Medicine</i> , 2022, 292, 116-126.	2.7	5
3	The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease. <i>Respiration</i> , 2022, 101, 717-727.	1.2	18
4	CMV-specific Cell-Mediated Immunity Predicts High level of CMV Replication after Prophylaxis withdrawal in Lung Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 526-531.	1.9	13
5	Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. <i>Internal Medicine Journal</i> , 2021, 51, 355-365.	0.5	30
6	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 384-392.	0.4	6
7	COVID-19 in lung transplant recipients: A multicenter study. <i>American Journal of Transplantation</i> , 2021, 21, 1816-1824.	2.6	56
8	Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study. <i>Archivos De Bronconeumologia</i> , 2021, 57, 690-690.	0.4	0
9	From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?. <i>Advances in Therapy</i> , 2021, 38, 1860-1875.	1.3	3
10	Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Physiology</i> , 2021, 12, 631326.	1.3	4
11	Hipertensin pulmonar tromboemblica crnica en Espaa: unacada de cambio. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 384-392.	0.6	9
12	Long-term results of sirolimus treatment in lymphangiomyomatosis: a single referral centre experience. <i>Scientific Reports</i> , 2021, 11, 10171.	1.6	9
13	Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response. <i>Cells</i> , 2021, 10, 1688.	1.8	8
14	Is there a procoagulant state long-term after lung transplantation? A prospective study. <i>Respiratory Medicine</i> , 2021, 188, 106584.	1.3	1
15	Near-normal aerobic capacity in long-term survivors after lung transplantation. <i>ERJ Open Research</i> , 2021, 7, 00381-2020.	1.1	1
16	Acute respiratory failure among lung transplant adults requiring intensive care: Changing spectrum of causative organisms and impact of procalcitonin test in the diagnostic workup. <i>Transplant Infectious Disease</i> , 2020, 22, e13346.	0.7	3
17	Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation. <i>PLoS ONE</i> , 2020, 15, e0226488.	1.1	8
18	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. <i>Genes</i> , 2020, 11, 1158.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndromeâ€A consensus report from the Pulmonary Council of the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 483-492.	0.3	190
20	Community-acquired Respiratory Viruses Are a Risk Factor for Chronic Lung Allograft Dysfunction. <i>Clinical Infectious Diseases</i> , 2019, 69, 1192-1197.	2.9	54
21	Proximal pulmonary arterial wall disease in patients with persistent pulmonary hypertension after successful leftâ€sided valve replacement according to the hemodynamic phenotype. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	0.8	4
22	Resultados del retrasplante pulmonar por disfunci3n cr3nica del injerto pulmonar en un centro trasplantador: Hospital Vall D™Hebron de Barcelona. <i>Archivos De Bronconeumologia</i> , 2019, 55, 134-138.	0.4	9
23	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. <i>International Journal of Cardiology</i> , 2019, 275, 158-164.	0.8	11
24	Gua de diagn3stico y tratamiento de la hipertensi3n pulmonar: resumen de recomendaciones. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.4	26
25	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.4	30
26	Lung transplantation in systemic sclerosis: A single center cohort study. <i>Joint Bone Spine</i> , 2018, 85, 79-84.	0.8	18
27	Procalcitonin accurately predicts lung transplant adults with low risk of pulmonary graft dysfunction and intensive care mortality. <i>Journal of Critical Care</i> , 2018, 44, 142-147.	1.0	8
28	Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. <i>Transplantation</i> , 2018, 102, e439-e446.	0.5	5
29	An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe. <i>European Respiratory Journal</i> , 2017, 49, 1600484.	3.1	43
30	High sensitivity and negative predictive value of theDETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. <i>Arthritis Research and Therapy</i> , 2017, 19, 135.	1.6	19
31	Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation. <i>Respiratory Research</i> , 2017, 18, 85.	1.4	11
32	Risk factors, survival, and impact of prophylaxis length in cytomegalovirusseropositive lung transplant recipients: A prospective, observational, multicenter study. <i>Transplant Infectious Disease</i> , 2017, 19, e12694.	0.7	14
33	<scp>BALF</scp> cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients. <i>Clinical Transplantation</i> , 2017, 31, e12898.	0.8	27
34	Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study. <i>Transplant International</i> , 2017, 30, 1266-1274.	0.8	7
35	Epidemiology and Risk Factors for Cancer After Lung Transplantation. <i>Transplantation Proceedings</i> , 2017, 49, 2285-2291.	0.3	19
36	Lung and heart-lung transplantation in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2017, 12, e0187811.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Molecular Analysis of BMPR2 , TBX4 , and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 1011-1019.	0.4	25
38	KL-6 in serum as a biomarker for differentiation of chronic allograft dysfunction in lung transplant. Preliminary results. , 2016, , .		0
39	Hypogammaglobulinemia in lung transplant candidates. , 2016, , .		0
40	Characteristics of Candidates for Lung Transplantation Due to Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency Emphysema. Archivos De Bronconeumologia, 2015, 51, 379-383.	0.4	0
41	Caractersticas de la poblacin candidata a trasplante pulmonar por enfermedad pulmonar obstructiva crnica y por enfisema secundario a dficit de alfa 1 antitripsina. Archivos De Bronconeumologia, 2015, 51, 379-383.	0.4	3
42	A founder <i>EIF2AK4</i> mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clinical Genetics, 2015, 88, 579-583.	1.0	57
43	Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplantation Reviews, 2015, 29, 85-92.	1.2	45
44	Pharmacokinetic Study of Conversion from Tacrolimus Twice-Daily to Tacrolimus Once-Daily in Stable Lung Transplantation. Transplantation, 2014, 97, 358-362.	0.5	16
45	High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosis. Clinical Transplantation, 2014, 28, 743-748.	0.8	5
46	Direcciones futuras en el trasplante pulmonar. Archivos De Bronconeumologia, 2014, 50, 1-2.	0.4	0
47	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplantation Reviews, 2014, 28, 84-91.	1.2	65
48	Impairment of pulmonary vascular reserve and right ventricular systolic reserve in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2014, 14, 69.	0.8	23
49	Future Directions in Lung Transplant. Archivos De Bronconeumologia, 2014, 50, 1-2.	0.4	101
50	Inhaled Iloprost Plus Oral Sildenafil in Patients With Severe Pulmonary Arterial Hypertension Delays the Need for Lung Transplantation. Transplantation Proceedings, 2013, 45, 2347-2350.	0.3	12
51	Biomarkers of Pulmonary Rejection. Transplantation Proceedings, 2013, 45, 3163-3169.	0.3	19
52	The Spanish Lung Transplant Registry: First Report of Results (20062010). Archivos De Bronconeumologia, 2013, 49, 70-78.	0.4	13
53	Acute absolute vasodilatation is associated with a lower vascular wall stiffness in pulmonary arterial hypertension. International Journal of Cardiology, 2013, 164, 227-231.	0.8	17
54	Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensin arterial pulmonar o hipertensin pulmonar tromboemblica crnica. Archivos De Bronconeumologia, 2013, 49, 181-188.	0.4	38

#	ARTICLE	IF	CITATIONS
55	In Vivo Assessment of Pulmonary Arterial Wall Fibrosis by Intravascular Optical Coherence Tomography in Pulmonary Arterial Hypertension: A New Prognostic Marker of Adverse Clinical Follow-Up. Open Respiratory Medicine Journal, 2013, 7, 26-32.	1.3	23
56	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. European Respiratory Journal, 2012, 40, 596-603.	3.1	342
57	Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension. Applied Health Economics and Health Policy, 2012, 10, 175-188.	1.0	17
58	613 Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Results from the Spanish Registry. Journal of Heart and Lung Transplantation, 2012, 31, S211-S212.	0.3	0
59	Mortality-Related Risk Factors in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment. Open Journal of Respiratory Diseases, 2012, 02, 17-24.	0.1	1
60	A Retrospective 12-Month Study of Conversion to Everolimus in Lung Transplant Recipients. Transplantation Proceedings, 2011, 43, 2693-2698.	0.3	20
61	Guidelines for the Selection of Lung Transplantation Candidates. Archivos De Bronconeumologia, 2011, 47, 303-309.	0.4	7
62	Normativa para la selecci3n de pacientes candidatos a trasplante pulmonar. Archivos De Bronconeumologia, 2011, 47, 303-309.	0.4	23
63	Combination Therapy for Pulmonary Arterial Hypertension. Archivos De Bronconeumologia, 2009, 45, 36-40.	0.4	3
64	Double-lung Transplantation in 15 Patients With Pulmonary Hypertension. Archivos De Bronconeumologia, 2009, 45, 366-370.	0.4	2
65	New Concepts in the Invasive and Non Invasive Evaluation of Remodelling of the Right Ventricle and Pulmonary Vasculature in Pulmonary Arterial Hypertension. Open Respiratory Medicine Journal, 2009, 3, 31-37.	1.3	9
66	Standards of Care in Pulmonary Hypertension. Archivos De Bronconeumologia, 2008, 44, 87-99.	0.4	8
67	Urgent Lung Transplantation in Spain. Transplantation Proceedings, 2005, 37, 3987-3990.	0.3	19
68	Lung transplantation for emphysema. Lung hyperinflation: incidence and outcome. Transplant International, 2004, 17, 810-814.	0.8	14